Piper Sandler raised the firm’s price target on Dyne Therapeutics to $29 from $27 and keeps an Overweight rating on the shares following positive Phase I/II ACHIEVE data and positive Phase I/II DELIVER data. The firm notes Dyne will report more data and plans to start registrational cohorts in both studies by year-end 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Dyne Therapeutics initiated with a Buy at H.C. Wainwright
- Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
- Dyne Therapeutics to Present at February Investor Conferences
- Dyne Therapeutics resumes trading, up 29% after report of takeover interest
